|Bid||82.77 x 800|
|Ask||0.00 x 900|
|Day's range||81.80 - 83.24|
|52-week range||65.25 - 92.64|
|Beta (5Y monthly)||0.47|
|PE ratio (TTM)||20.21|
|Forward dividend & yield||2.44 (2.94%)|
|Ex-dividend date||14 Sep 2020|
|1y target est||N/A|
Prostate cancer is the second-most common type of cancer in men worldwide, while ovarian cancer is the fifth most common cause of cancer death in Europe. The EMA recommendation follows positive regulatory updates for Lynparza, which AstraZeneca has developed with Merck & Co Inc as it faces competition from British rival GlaxoSmithKline on cancer drugs.
Seattle Genetics (SGEN) strikes a couple of deals with Merck to co-develop ladiratuzumab vedotin for breast cancer and other solid tumors. Also, Merck will market the company's Tukysa in some places.
Merck (MRK) buys rights to co-develop/co-commercialize Seattle Genetics' ladiratuzumab vedotin. It acquires exclusive license to commercialize Tukysa for HER2-positive cancers in Asia, the Middle East and Latin America